ASH 2022 Conference Coverage
ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Pts With Hypomethylating Agent Failure MDS
By
ASH 2022 Conference Coverage
FEATURING
David Sallman
By
ASH 2022 Conference Coverage
FEATURING
David Sallman
Login to view comments.
Click here to Login
